Info

🌱 來自: Antibody Drug Conjugates

Ado-trastuzumab emtansine

• Mechanism: HER2-targeted antibody-drug conjugated to the antimicrotubular maytansinoid agent, mertansine (DM1)
• Dosing: 3.6 mg/kg every 3 wks, no renal or hepatic adjustments
• PK/PD: T1/2 ∼4 d
• AEs: Hepatotoxicity, ↓ LVEF, pancytopenia, GI tox, neuropathy, ↓ K
• DDI: CYP3A4 substrate